SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas move to record highs is being linked to KFCs planned switch from Pepsi to Coke across its U.S. restaurants, which traders view as a distribution win amid KOs outperformance of Pepsi. The reaction is broadly bullish, though some traders caution that the rally has stretched the stocks valuation.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is drawing attention after a prolonged selloff in Chinese internet stocks, with traders split between bottom-fishing for an oversold bounce and expecting further weakness. Bulls point to depressed valuations and technical support, while bears cite Chinas weak demand, limited market inflows, and persistent policy and geopolitical risks.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures trading around weather forecasts and EIA storage data. Traders are split on whether heat and tighter storage can offset a mild shoulder-season outlook, strong production, and returning pipeline and LNG flows; many also caution that BOILs leverage and futures-roll decay amplify the risk.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

A prolonged selloff in obesity-focused biotech has put GPCR under scrutiny, with traders debating whether the drop reflects sector weakness and skepticism about alenigliprons efficacy, tolerability and long Phase 3 timeline. Some investors view the companys cash and oral obesity pipeline as undervalued, while others cite intense competition and clinical risks; buyout talk remains speculative.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention over lawsuits alleging brake-master-cylinder failures and 6.2L V8 engine defects, though the cases remain unresolved and no class has been certified. Traders are also weighing declining Q3 U.S. sales and weak EV demand against bullish technical setups and positioning ahead of earnings.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnights mainnet launch and ecosystem announcements, including Google and Vodafone validator participation and planned financial-use cases, are driving attention to the privacy-focused Cardano network. Traders are split between optimism about adoption and concern that airdrop redemptions and token selling are weighing on NIGHT, while some question the networks decentralization and near-term traction.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

ICPs choppy price action and repeated failed breakouts are dominating discussion, with bearish traders citing weak volume and continued selling while long-term bulls point to its decentralized cloud and AI infrastructure thesis, network usage, and token-supply changes. The community remains divided over whether those fundamentals can translate into stronger adoption and token demand.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

LINK is drawing attention amid volatile, choppy price action, with traders debating whether recent weakness is a buying opportunity or a failed breakout. Bullish holders point to Chainlinks institutional and tokenization integrations, while skeptics question whether network adoption translates into value for the LINK token and some blame selling pressure without evidence.

WorldFinancial

World Liberty Financials preliminary conditional OCC approval to establish a national trust bank for its USD1 stablecoin is driving attention, with bullish traders viewing future banking operations and token utility as potential catalysts. Others say the news has not translated into sustained token strength and raise concerns about the project and its selloff; predictions of a low-float squeeze remain speculative.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus completed enrollment in its expanded pancreatic-cancer IMPACT study and a pipeline of upcoming clinical milestones, including updates in glioblastoma and ReSTART; traders view the enrollment expansion as encouraging and are accumulating shares ahead of data. Sentiment is largely bullish, though some traders point to pullbacks and resistance near recent highs and note that clinical readouts remain uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer...

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss...

TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits Expectations

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on...

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recom...

TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday

TScan Therapeutics (NASDAQ:TCRX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. One...

TScan Therapeutics (NASDAQ:TCRX) Shares Up 3%  - Here's What Happened

TScan Therapeutics (NASDAQ:TCRX) Stock Price Up 3% - Here's What Happened...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.

Tscan Therapeutics Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$TCRX beaten down but thesis stronger than price implies.

Pivot to in vivo cell therapy broadens acquirer universe massively. Ex vivo = 4-5 names (Kite, Novartis, BMS, J&J). In vivo = any large pharma with oncology + LNP capability. In 2024-25 alone ~$6.1B deployed in this space: AbbVie $2.1B (Capstan), Lilly $7B (Kelonia), BMS $1.5B (Orbital), AZ $1B (EsoBiotec). One of biotech's hottest M&A categories.

All of these acquisitions were preclinical or very early Phase 1. 

What caught my eye: new fund just filed 13G at 5.4% — Readout Capital. CIO: ex-Lion Point biotech PM (event-driven). CSO: Dr. James Dahlman — MIT/Harvard PhD, ex-Google Ventures, founded Guide Therapeutics (sold to Beam for $440M). His entire career is LNP-based in vivo RNA delivery — exactly the technology behind TCRX's pivot. Filed 3 weeks post-reorg. High-conviction scientific bet, not a passive screen.

Net cash ~$0.52/share vs $0.21 stock. Watching closely.

Lima B

$TCRX why are you so scared? I’m averaging down heavily at this point. The catalyst that caused this drop is actually strengthening the company’s balance sheet. In bio, I have seen $TRIL go from $0.17 to near $20. The risk to reward ratio is very attractive at this point.

Shaan

$TCRX can anybody verify cash and os count on this turd? is it cash = 100m+ and OS count =  63m or so

$TCRX reveals CFO and CMO departures with lump-sum cash awards of $85K and $125K under separation agreements.

jorge .miguel

$TCRX scam and trash and useless stock. If you bought shares and are bullish you deserve to be atomised

snailman123

$TCRX never take advice from a bio guy who spams boards claiming to have had many concussions in the past… T cell companies there are out 100 of them out there.. just waiting to get back to even but I’ll have to go up over 100% from here

Feed

News

Sentiment

Earnings

Fundamentals

Info

TCRX Tscan Therapeutics Inc

Fundamentals

Latest TCRX News